MMP2 and trichorhinophalangeal syndrome type I: Previous studies show that miR-222-3p has an oncogenic effect by regulating MMP2 (matrix metalloproteinaza), MMP9, TRPS1 (trichorhinophalangeal syndrome type 1), and CDKN1C/p57 (cyclin-dependent kinase inhibitor 1C) [35,46,47].